Amorphous Solid Dispersion: Strategies in Early Stage Development and Technology Choice

14 December 2020 14:30 - 15:05

  • Many ASD technologies are available at the industrial scale
  • Selection of the right ASD technology is strategic for the future pre-clinical and clinical development and depends on:
  • Quantity of API available
  • Stage of development (feasibility studies, formulation/process development)
  • Formulation selection
  • CMC prerequisite (physical and chemical stability, solubility and dissolution improvement)

Philippe Lienard, Pre-Development Science Leader, Sanofi